Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Elevation Oncology, Inc. (NASDAQ:ELEV) from Buy to Neutral and lowered the price target from $1 to $0.36. Elevation Oncology shares closed at $0.3843 on Monday.
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Elevation Oncology, Inc. (NASDAQ:ELEV) from Buy to Neutral and lowered the price target from $1 to $0.36. Elevation Oncology shares closed at $0.3843 on Monday.
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Elevation Oncology, Inc. (NASDAQ:ELEV) from Buy to Neutral and lowered the price target from $1 to $0.36. Elevation Oncology shares closed at $0.3843 on Monday. Full story available on Benzinga.com Read MoreACGL, ELEV, MCD, News, Top Downgrades, TTGT, Downgrades, Markets, Analyst Ratings, Trading Ideas, ACGL, BMG0450A1053, TTGT, US87874R1005, MCD, US5801351017, ELEV, News, Downgrades, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
